ArticleCureus2026
The Risk of Aspiration Is Low With Continuing Semaglutide During Elective Eye Surgery When Patients Receive Only Moderate Sedation.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The purpose of this study was to assess aspiration risk in patients undergoing elective eye surgery with moderate sedation as the anesthetic while taking the glucagon-like peptide type 1 receptor agonist (GLP-1RA) Ozempic formulation of semaglutide. Setting and design This retrospective observational study took place in Fleming Island Surgery Center and East West Surgery Center, Fleming Island, Florida. Methods Records of patients actively taking the Ozempic formulation of semaglutide and presenting for elective eye surgery from July 1, 2022, through December 31, 2023, were reviewed to determine the incidence of aspiration. The patient risk assessment included body mass index in kg/m2 (BMI), and medical history regarding diabetes mellitus (DM), gastroesophageal reflux disease (GERD), hiatal hernia (HH), and narcotic use. Analysis assessments included the time and dose of the last semaglutide administration (0-7 days, 8-14 days, or >14 days), type and duration of surgery, type of anesthesia or sedation, pre- and post-operative oxygen saturation (SpO2), respiratory problems, and post-operative nausea or vomiting (PONV). Results A total of 155 surgical records of patients actively taking semaglutide were identified and reviewed. The BMI range was 21-52; 143 cases had DM (all DM cases were type 2), 58 cases had GERD, and 12 cases had concurrent narcotic use. One hundred fifty-one patients received moderate sedation, two received intravenous propofol with local block, and two underwent general anesthesia. One hundred twenty of the 155 cases had taken semaglutide within one week of the surgery. There were no significant intra- or postoperative respiratory issues, PONV, or significant changes in the postoperative SpO2 in any of the patients. Conclusion There were no cases of aspiration or respiratory compromise in any patients who continued semaglutide at the time of their surgical procedure. In this study, continuing semaglutide while undergoing elective eye surgery with only moderate sedation for anesthesia did not pose an aspiration risk, minimized disruption to patient medical routines, and reduced the negative impact of procedure cancellation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.